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Breast cancer formation is considered to be multifactorial,
involving both genetic and environmental components. The effect
of environmental factors, which has been shown in migrant studies
(Ziegler et al, 1993), include diet (Hunter and Willett, 1993) or
polyaromatic hydrocarbons (PAHs) (Li et al, 1996). PAHs from
smoking or environmental sources can accumulate in breast and be
metabolized to active carcinogens, which may contribute to breast
carcinogenesis (Perera et al, 1995). Differences in bioactivation or
detoxification of carcinogens may therefore have a role in deter-
mining individual susceptibility to breast cancer.
Cytochrome P4501A1 (CYP1A1) is involved in metabolizing
PAHs. The metabolic intermediate is electrophilic, and can form
carcinogenic DNA adduct. In addition, CYP1A1 may be involved
in breast cancer via an oestrogen-related mechanism. Oestradiol is
metabolized by two competing pathways to form either inactive
2-hydroxyestrone or active 16a-hydroxyestrone (Ball et al, 1990);
level of the latter is often elevated in breast cancer, and may be
related to tumorigenesis (Fishman et al, 1984; Osborne et al,
1993). CYP1A1 polymorphism may affect the distribution of these
metabolites and then determine susceptibility to cancer (Yager,
1996; Zhu and Conney, 1998). Two major changes causing
CYP1A1 polymorphism are reported: the T-A to C-G transition in
the non-coding 3¢-flanking region, which introduces a new Msp1
restriction site, and the A-T to G-C transition in exon 7, resulting
in the replacement of an isoleucine (Ile) by valine (Val). For breast
cancer susceptibility, a study of African-American patients has
found a positive association with the Msp1, but not with the Ile/Val
polymorphism (Taioli et al, 1995). One Caucasian study revealed
a slightly elevated risk with Ile/Val polymorphism in post-
menopausal women (Ambrosone et al, 1995). In contrast, these
associations can not be confirmed by other studies (Bailey et al,
1998; Ishibe et al., 1998). The association of CYP1A1 with breast
cancer risk in Asian women has never been studied. Since ethnic
differences have frequently been seen in the relationship between
CYP1A1 polymorphism and cancer risk, it was of interest to
evaluate this relationship in Asian women, who show the lowest
incidence of breast cancer in the world.
Breast cancer incidence has increased about threefold in the past
two decades in Taiwan. Exposure to Western lifestyles is thought
to have a substantial impact on the risk (Yang et al, 1997).
Furthermore, increasing exposure to environmental pollutants, due
to economic development, has been noted in Taiwanese. Since
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Taiwan. Further study with a large sample size should be considered to address issues of interactions between CYP1A1 and other risk
factors.
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CYP1A1 is involved in the metabolism of both environmental
carcinogens and oestrogen, its polymorphism may contribute to
individual susceptibility to breast cancer. This study was
conducted to investigate such a hypothesis.
MATERIALS AND METHODS
Subjects, materials and questionnaire
One hundred and fifty female breast cancer patients and 150
healthy female controls who had given their informed consent
were enrolled. All breast cancer patients had pathologically
confirmed primary breast carcinoma, and all were diagnosed and
treated at the National Taiwan University Hospital between
January 1995 and June 1996. This sample of female patients
constituted about 50% of all the women with breast cancer
attending our breast cancer clinic during the study period; the
remaining patients were excluded due to the lack of sufficient
blood specimens. No significant differences were found in breast
cancer risk factor between the women selected and not selected.
The healthy controls were randomly selected from the health
examination clinic at the same hospital during the same study
period, and constituted about 10% of all women attending the
clinic. No significant differences were found in terms of socio-
economic status between those included and excluded. The control
subjects received a 1.5-day comprehensive health examination,
not sponsored by the national health insurance programme, and
showed no evidence of breast cancer, any suspicious precancerous
lesions of the breast, or other cancers. A thorough, structured
questionnaire was completed by both groups to provide relevant
information regarding risk factors of breast cancer. An experi-
enced research nurse was assigned to obtain this information.
Information collected included age at diagnosis, family history of
breast cancer (first-degree relatives), previous history of breast
biopsy, age at menarche and/or menopause, parity, age at first full-
term pregnancy (FFTP), number of pregnancies, history of breast-
feeding, use of oral contraceptives, hormone replacement therapy
(HRT), history of drinking alcohol and smoking cigarettes, ethnic
background, residence area, family income and education level.
The body mass index (BMI) and menopausal status were also
recorded. Women younger than 55 years who had undergone
hysterectomy, but not bilateral oophorectomy, were classified as
unknown in terms of their menopausal status. On the basis of
average family income and educational level, both case and
control groups showed a high degree of homogeneity, and almost
all (> 95% of both cases and controls) represented a population of
middle-class women in Taiwan.
A 10-ml sample of peripheral blood, collected in acetate–citrate
dextrose, was obtained from each breast cancer patient prior to
treatment and from each control subject; the buffy coats of these
specimens were prepared immediately and stored at –80°C until
extraction of the genomic DNA. Genomic DNA was obtained by
conventional phenol–chloroform extraction, followed by ethanol
precipitation and was stored at –20°C for genotype analyses.
Determination of CYP1A1 genetic polymorphism
Genotyping of the CYP1A1 Msp1 polymorphism was successfully
performed for 141 patients and 145 controls using the polymerase
chain reaction-restriction fragment length polymorphism (PCR-
RFLP) method (Kawajiri et al, 1990; Hayashi et al, 1991). In brief,
PCR amplification of a 340-base DNA fragment containing an
Msp1 restriction site was performed, using the primers 5¢-
TAGGAGTCTTGTCTCATGCCT-3¢(C44) and 5¢-CAGTGAA-
GAGGTGTAGCCGCT-3¢(C47). The reaction mixture contained
approximately 0.5 mg of genomic DNA, 0.5 units of Taq poly-
merase, 20 pmol of the pair of primers and 200 mM of dNTPs in a
total volume of 50 ml. PCR was performed at 95°C for 10 min for
the initial denaturation, following by 35 cycles of denaturation at
95°C for 30 s, annealing at 55°C for 30 s and extension at 72°C for
1 min. An aliquot of 12.5 ml of PCR product was digested with
Msp1, then electrophoresed on 3% agarose gels for 1 h, and
stained with ethidium bromide. Since the Msp1 variant allele
creates a new Msp1 restriction site in the PCR product, it was
identified by the presence of two bands on the gel. Three different
genotypes were defined for the individual polymorphisms, these
being the homozygous wild-type (no Msp1 site in either allele,
wt/wt), the heterozygous variant (an Msp1 site in one allele, wt/vt),
and the homozygous variant (an Msp1 site in both alleles, vt/vt).
The Ile/Val polymorphism was analysed in 143 cases and
145 controls using the PCR-RFLP method described by Oyama
et al 1995). The primers used were: 1A1S (5¢-GAACTGC-
CACTTCAGCTGTCT-3¢) and 1A1AS HincII (5¢-GAAAGAC-
CTCCCAGCGGTCA-3¢). The 1A1AS HincII has a mismatch at
the third residue (T) from the 3¢ end of the primer that introduces
an adenine residue at the second position of codon 463 and creates
a HincII site next to the Val polymorphism at codon 462 by further
PCR as above. The PCR products were digested with HincII and
electrophoresed on 3% agarose gels and three different genotypes
were defined, consisting of the homozygous wild-type (Ile/Ile),
the heterozygous variant (Ile/Val) and the homozygous variant
(Val/Val).
Statistical analysis
Individual risk factors were first examined for their relationship to
the risk of breast cancer using the c2 test or t-test; if necessary, the
Mantel c2 test for trends was used to examine the dose–response
relationship for the breast cancer risk estimates of various
categories of genetic polymorphism; if a significant result was
obtained, they were further examined using a multivariate logistic
regression model. To obtain a model with biological plausibility,
we included established risk factors in the logistic models regard-
less of statistical significance: the age of study participants,
positive family history of breast cancer, the age at menarche and
the age at FFTP (Kelsey, 1993). Next, the contribution of CYP1A1
polymorphism on breast cancer risk was evaluated under the
condition that established risk factors or other significant risk
factors were determined. A backward elimination procedure
(Kleinbaum et al, 1982) was used to select the optimal model.
Unconditional logistic regression analyses were performed to
estimate multivariate-adjusted ORs (aORs) and their 95% CIs. All
P-values were two-tailed.
RESULTS
Table 1 shows all putative risk factors of breast cancer investigated
in the present study. The mean age (± standard deviation (s.d.)) of
the 150 breast cancer patients was 49.57 ± 11.34 years (range
26–82), which was slightly lower than that of the healthy controls
(51.11 ± 11.82 years; range 25–84) (P > 0.05). The patients and1840 C-S Huang et al
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controls were very similar in terms of ethnic background and resi-
dence area (P > 0.05). The controls had a slightly higher family
income and education level than the patients, but the difference
was not significant (P > 0.05). Of the established or likely risk
factors for breast cancer examined in this study, the following were
found to be significantly associated with cancer risk by univariate
analysis: young age at menarche, nulliparity or an older age at
FFTP (³ 30 years), fewer number of full-term pregnancies, no
history of breast-feeding, a history of HRT, current or previous
history of cigarette smoking and a lower BMI. Further multivariate
analysis simultaneously taking into account established risk
factors or significant risk factors determined by univariate
analysis, revealed that a younger age at menarche, nulliparity or
an older age at FFTP, a history of HRT, and no history of breast-
feeding were independent risk factors with a significant OR
(Table 1). Family history (in first-degree relatives) was not found
to be a significant risk factor by univariate and multivariate
analysis. A similar proportion of patients and controls (3.6% and
3.8%) reported a positive family history of breast cancer. As our
controls were from the group asking for health examination not
sponsored by national health insurance, they might represent a
group of women showing more concern about their health. In an
earlier (1993–1994) case control study of breast cancer risk factors
in the same hospital using breast cancer patients as the cases and
cancer-free patients from other wards, such as ophthalmology
ward, as the controls, 3.43% of the 175 cases and 0.44% of the 457
controls reported a positive family history of breast cancer in their
first degree relatives (Chie et al, 1997, 1998). In the present study,
the non-significant result for family history as a breast cancer risk
factor therefore might result from the high proportion of controls
with a family history.
The frequency distributions of the different genotypes for the
CYP1A1 Msp1 and Ile/Val polymorphisms are shown in Table 2.
A few specimens were not included in the analyses because of
the poor quality of the DNA. The proportion (> 10% of variant
CYP1A1 Msp1 genotype in controls) of women harbouring variant
genotype was much higher than that (< 5%) observed in Western
women, which results in a higher statistical power to evaluate such
association in our population. A trend of increasing risk for Ile/Val
heterozygotes and Val/Val homozygotes was suggested, particu-
larly in postmenopausal women, but was not statistically signifi-
cant (P for trend = 0.07). In contrast, a significant increase in the
risk of developing breast cancer was observed in the variant
CYP1A1 Msp1 genotypes in postmenopausal women (P for
trend = 0.04). On the basis of the observation that a non-significant
OR for the group of heterozygous variant was found as compared
Table 1 Univariate and multivariate analyses of risk factors for breast cancer in breast cancer patients (n = 150) and control subjects (n = 150), Taiwan
Characteristics Case Control OR P aOR (95% CI)a
Age, year, mean ± s.d
49.57 ± 11.34 51.11 ± 11.82 – 0.25 0.98 (0.96–1.00)
Age, year, at menarche, mean ± s.d.
14.23 ± 1.78 14.73 ± 1.86 – 0.02 –
Menopausal status
Premenopausal 57 (42.5) 55 (41.7) 1.00 0.89 NS
Postmenopausal 77 (57.5) 77 (58.3) 0.96
Family history of breast cancer in mother or sister
No 134 (96.4) 128 (96.2) 1.00 0.94 1.04 (0.25–4.23)
Yes 5 (3.6) 5 (3.8) 0.96
Age at menarche, year
> 13 82 (59.0) 95 (71.4) 1.00 0.03 1.00
≤ 13 57 (41.0) 38 (28.6) 1.74 1.80 (1.1–3.1)
No. of full-term pregnancy
> 3 25 (18.0) 49 (37.7) 1.00 0.001 NS
1–3 100 (71.9) 73 (56.2) 2.68 (trend test)
Nulliparity 14 (10.1) 8 (6.1) 3.43
Age at first full-term pregnancy, year, or nulliparity
< 30 102 (73.4) 118 (88.7) 1.00 0.001 1.00
³ 30 or nulliparity 37 (26.6) 11 (11.3) 3.89 2.68 (1.4–5.4)
Breast-feeding
Yes 64 (46.4) 92 (70.2) 1.00 0.001 NS
No 74 (53.6) 39 (29.8) 2.73
History of cigarette smoking
Never 131 (94.2) 131 (98.5) 1.00 0.06 1.00
Ever 8 (5.8) 2 (1.5) 4.00 5.50 (1.3–38.2)
Use of hormone replacement therapy
Never 118 (86.1) 126 (94.7) 1.00 0.02 1.00
Ever 19 (13.2) 7 (5.3) 2.90 1.39 (1.4–9.1)
Body mass index, kg/m2
<25 114 (82.0) 90 (67.7) 1.00 0.01 NS
³ 25 25 (18.0) 43 (32.3) 0.46
Use of oral contraceptives
Never 117 (85.4) 108 (81.8) 1.00 0.43 NS
Ever 20 (14.6) 24 (18.2) 0.77
* aOR, adjusted odds ratio from unconditional logistic regression which included the following risk factors: the age of study participants, positive family history
of breast cancer, the age at menarche, the age at FFTP or nulliparity, breast feeding, history of HRT and smoking status. NS, not statistically significant at
P = 0.05 in logistic regression; these factors were removed from the final model.CYP1A1 polymorphism and breast cancer risk 1841
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to the group of homozygous wild-type, we classified the genotypes
of the study subjects into two groups, homozygous variant and
non-homozygous variant (consisting of the homozygous wild-type
and the heterozygous variant) in the following analysis. The
proportion of homozygous variants versus non-homozygous vari-
ants for the Msp1 polymorphism in patients with breast cancer was
significantly higher than that in the control group (OR, 2.21; 95%
CI 1.11–1.41) by univariate analysis. Interestingly, this association
was more obvious in postmenopausal women (OR, 2.95; 95% CI
1.17–7.58), but not significant in premenopausal women. In
contrast, the proportion of the homozygous variant of the Ile/Val
polymorphism was not significantly different between breast
cancer patients and healthy controls, though a slightly significant
association was seen in postmenopausal women.
Multivariate logistic regression analysis was performed to
assess the effect of CYP1A1 genetic polymorphism on breast
cancer risk after adjusting for other established or significant risk
factors, i.e. the age of study participants, positive family history of
breast cancer, early menarche, nulliparity or an older age at FFTP,
a history of HRT and smoking (Table 3). The results showed that
the homozygous variant of the CYP1A1 Msp1 polymorphism
remained a significant risk factor for breast cancer (aOR, 1.98;
95% CI 1.01–4.00). In contrast, the CYP1A1 Ile/Val poly-
morphism gave no correlation with breast cancer risk in the
multivariate model (aOR, 1.07; 95% CI 0.64–1.78).
Further analysis, stratified by different risk factors, was
performed to explore possible mechanisms of breast tumorigenesis
related to CYP1A1. Since the number of women with a history of
Table 2 Distribution of CYPIA1 genetic polymorphism between breast cancer patients and controls in Taiwan
Genotype No. of cases (%) No. of controls (%) OR (95% CI) P for trend
Total women
Msp1 polymorphism
wt/wt 49 (34.7) 48 (33.1) 1.00 (referent) 0.25
wt/vt 60 (42.6) 80 (55.2) 0.73 (0.42–1.28)
vt/vt 32 (22.7) 17 (11.7) 1.84 (0.86–4.00)
Ile/Val polymorphism
Ile/Ile 71 (49.7) 80 (55.2) 1.00 (referent) 0.70
Ile/Val 64 (44.8) 53 (36.5) 1.36 (0.81–2.27)
Val/Val 8 (5.5) 12 (8.3) 1.75 (0.26–2.12)
Premenopausal women
Msp1 polymorphism
wt/wt 27 (42.9) 20 (31.3) 1.00 (referent) 0.59
wt/vt 25 (39.7) 36 (56.3) 0.51 (0.22–1.19)
vt/vt 11 (17.4) 8 (12.4) 1.02 (0.30–3.43)
Ile/Val polymorphism
Ile/Ile 34 (54.0) 31 (48.4) 1.00 (referent) 0.14
Ile/Val 28 (44.4) 25 (39.1) 1.02 (0.46–2.25)
Val/Val 1 (1.6) 8 (12.5) 0.11 (0.01–1.00)
Postmenopausal women
Msp1 polymorphism
wt/wt 22 (28.2) 28 (34.6) 1.00 (referent) 0.04
wt/vt 35 (44.9) 44 (54.3) 1.01 (0.47–2.20)
vt/vt 21 (26.9) 9 (11.1) 2.97 (1.03–8.72)
Ile/Val polymorphism
Ile/Ile 37 (46.3) 49 (60.5) 1.00 (referent) 0.07
Ile/Val 36 (45.0) 28 (34.6) 1.70 (0.84–3.45)
Val/Val 7 (8.7) 4 (4.9) 2.32 (0.55–10.3)
Table 3 Unconditional logistic regression analysis of multiple risk factors of
breast cancer in Taiwan
Risk factor Comparison OR 95% CI
CYP1A1 Msp1 vt/vt vs wt/vt+wt/wt 1.98a 1.01–3.99a
Age of study participant ± 1 year 0.98 0.96–1.00
Family history of breast cancer
Yes vs No 1.12 0.27–4.55
Age at menarche ≤13 vs > 13 1.82 1.06–3.18
Age at FFTP or nulliparity ³30 or nulliparity vs < 30
2.59 1.32–5.27
HRT Yes vs No 3.60 1.47–9.78
Smoking Yes vs No 5.10 1.14–35.9
aThe contribution of CYP1A1 Msp1 polymorphism to breast cancer
development was adjusted by all known or significant risk factors included in
the model (age, postive family history of breast cancer, age at menarche,
age at FFTP or nulliparity, history of HRT and smoking status).
Table 4 Unconditional logistic regression analysis of CYP1A1 Msp1
polymorphism in relation to breast cancer risk in postmenopausal women
without a history of smoking or HRT
Risk factor Comparison OR 95% CI
CYP1A1 Msp1 vt/vt vs wt/vt+wt/wt 2.82* 1.02–7.69a
Age at menarche ≤ 13 vs > 13 2.53 1.14–5.64
Age at FFTP or
nulliparity
³ 30 or nulliparity vs <30 2.86 0.96–8.49
aThe contribution of CYP1A1 Msp1 polymorphism to breast cancer
development in postmenopausal women without a history of smoking or HRT
was adjusted by the age at menarche and the age at FFTP or nulliparity.1842 C-S Huang et al
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smoking or HRT was very small in this study (as it is in Taiwanese
women in general), a multivariate logistic regression analysis of
individual subgroups based on smoking or HRT status was not
feasible, and we therefore restricted our analysis to post-
menopausal women without any history of smoking or HRT
(Table 4). We did not include the age of study participants and
positive family history of breast cancer in the model, because that
age distribution in these women was relatively homogenous and
family history does not seem to be related to late-onset (post-
menopausal) breast cancer. The results showed that CYP1A1
Msp1 polymorphism remained a significant risk factor (aOR, 2.82;
95% CI 1.02–7.69). Further stratification of this specific subgroup
of women by age at menarche revealed that CYP1A1 polymor-
phism was particularly significant in women with early menarche,
the risk of breast cancer being eight times as great in women with
the homozygous variant as in those with the non-homozygous
variants (95% CI 1.23–158). In contrast, this association was not
obvious in women with late menarche (P = 0.06).
DISCUSSION
Our study shows that a homozygous variant of the CYP1A1 Msp1
polymorphism was a significant risk factor associated with breast
cancer, independent of other established risk factors. This study is
the first to evaluate such an association in a Chinese population,
having the lowest incidence (20 cases per 100 000 women per
year) in the world (Lo et al, 1998). No association of the homozy-
gous CYP1A1 Val/Val genotype and breast cancer risk was seen;
this is consistent with the results of an in vitro study showing that
the Ile and Val forms of CYP1A1 have a similar metabolic
capacity to bioactivate carcinogens (Zhang et al, 1996).
Since CYP1A1 is involved in the activation of procarcinogens,
it is reasonable to observe an association between CYP1A1 poly-
morphism and cancer risk, especially in cancers caused by
chemical carcinogens. For example, it has frequently been
reported that an increased risk of lung cancer is related to variant
CYP1A1 Msp1 genotypes (Kawajiri et al, 1993; Kihara and Noda,
1995; Xu et al, 1996); however, the results vary among ethnic
groups (Drakoulis et al, 1994; Hirvonen et al, 1992; Alexandrie
et al, 1994). In breast cancer, a significant association related to
Msp1 polymorphism was found in African-American patients
(Taioli et al, 1995); however, this was not apparent in Caucasians
(Bailey et al, 1998; Ishibe et al, 1998). These discrepancies in
cancer risk associated with CYP1A1 variant genotypes may be
explained, in part, by ethnic differences in the frequency of the
genotypic polymorphism. Almost all studies assessing the relation
between CYP1A1 and cancer are based on a case control design.
Whether CYP1A1 polymorphism is significant in such a design
depends on the frequency of variant genotypes in the controls as
well as in the cases. The frequencies of a variant allele or genotype
vary markedly between ethnic groups, being much higher in the
Asian than in the Caucasian, with an intermediate value in the
African-American. The significantly low prevalence of a variant
allele and especially the homozygous variant genotype in
Caucasians results in a lower statistical power for detecting an
effect of CYP1A1 polymorphism on cancer risk. In contrast, in
Asian studies, including our own, more than 10% of the study
populations possess variant genotypes, and, therefore, adequate
statistical power facilitates the evaluation of such an association.
Ethnic differences in CYP1A1 polymorphism related to cancer
risk may also be attributable to difference in exposure ‘dosage’ to
procarcinogens in the different populations. Specific genotypes
conferring protection/susceptibility to cancer risk commonly
reveal their protective/promoting effect in subjects exposed to a
‘normal dose’ of procarcinogens. For example, the greatest
incremental lung cancer risk (sevenfold) for the ‘susceptible’
CYP1A1 genotype was seen in light smokers, whereas heavy
smokers with this genotype had less than twice the risk of
heavy smokers without the genotype (Nakachi et al, 1991). A
study also showed that the increased level of carcinogen-DNA
adduct related to genetic polymorphism was seen only in individ-
uals exposed to levels of procarcinogens below the average level,
while adduct levels in individuals exposed to higher levels were
similar, regardless of the genetic status of their susceptibility
genes (Kato et al, 1995). Thus, the significant effect seen with
CYP1A1 in relation to breast cancer risk in our population, but not
in Caucasian populations, might be due to the relatively lower
levels of procarcinogens among Taiwanese women. Supporting
this hypothesis, it is notable that Asian women have, on average,
20% lower serum oestradiol levels than Western women
(Bernstein et al, 1990).
In this study, the association between CYP1A1 polymorphism
and breast cancer was more striking in postmenopausal women.
Since carcinogenesis requires an extended period to accumulate
genetic mutations, the promoting effect of carcinogens, including
oestrogen, may affect the breast tissue in the premenopausal period
and contribute to the development of postmenopausal breast
cancer. Thus, an increased cancer risk related to CYP1A1 geno-
types in postmenopausal women may be due to the long period of
time required for CYP1A1-related mechanisms to accumulate
their carcinogenic effect. Our observation that the CYP1A1-Msp1
genotype-related susceptibility to breast cancer was also more
evident in women over 50 years of age (OR in women > 50 years,
2.67, P = 0.03 vs OR in women ≤ 50 years, 1.73, P = 0.24),
regardless of their menopausal status, supports this idea.
PAHs and oestrogen are two CYP1A1-related procarcinogens.
However, our analysis focusing on postmenopausal women
without any history of smoking or HRT still showed a significantly
increased risk posed by the CYP1A1 variant. This finding suggests
that, for these women, CYP1A1-related carcinogen might be from
source other than smoking and HRT. Whether these undefined
carcinogens are related to increasing amount of pollutants,
including environmental oestrogen (such as pesticides) or PAHs
(from many air pollution sources) due to economic boom in
Taiwan, is an interesting hypothesis remaining to be explored.
Furthermore, in postmenopausal women without smoking and
HRT, the breast cancer risk related to CYP1A1 was more obvious
in women with early menarche. Women with early menarche had
been exposed to estrogen for a longer period of time, which might
amplify the effect of the CYP1A1 variants. However, due to
limited sample size of these subgroups in this study, these inter-
pretations should be confirmed by further research.
Our study shows that the CYP1A1 Msp1 polymorphism is a
significant susceptibility factor for breast cancer among post-
menopausal Chinese women in Taiwan. For a population with a
relatively higher frequency of the homozygous variants of
CYP1A1 Msp1, such findings not only provide clues toward
understanding the role of CYP1A1-related carcinogens during
breast tumorigenesis, but are also of special public health impor-
tance. Although CYP1A1 poses a low individual risk, it is not an
uncommon genetic trait and could be an important determinant
of population risk.CYP1A1 polymorphism and breast cancer risk 1843
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